370879-78-0

Basic information

• Product Name: 3-Bromo-5-propoxypyridine
• Synonyms: 3-Bromo-5-propoxypyridine
• CAS NO: 370879-78-0
• Molecular Formula: C₈H₁₀BrNO
• Molecular Weight: 216.0751
• Mol File: 370879-78-0.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Room temperature.
• CAS DataBase Reference: 3-Bromo-5-propoxypyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Bromo-5-propoxypyridine(370879-78-0)
• EPA Substance Registry System: 3-Bromo-5-propoxypyridine(370879-78-0)

Safety Data

• Hazardous Substances Data: 370879-78-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
3-Bromo-5-propoxypyridine is used as a building block for the synthesis of a variety of organic compounds, leveraging its unique structure and reactivity to facilitate the creation of complex molecules.
Used in Pharmaceutical Applications:
In the pharmaceutical industry, 3-Bromo-5-propoxypyridine is utilized as a key intermediate in the development of new drugs, contributing to the advancement of medicinal chemistry through its potential to form the basis of novel therapeutic agents.
Used in Agrochemical Production:
3-Bromo-5-propoxypyridine is also employed in the agrochemical sector, serving as a precursor in the synthesis of compounds used in agricultural chemicals, thereby supporting crop protection and enhancement efforts.
Used in Medicinal Chemistry Research:
3-Bromo-5-propoxypyridine is used as a subject of study in medicinal chemistry research to explore its potential biological activities, with the aim of discovering new therapeutic applications and expanding the understanding of its interactions with biological systems.

Upstream product

• 625-92-3 3,5-dibromopyridine 
• 71-23-8 propan-1-ol 
• 74115-13-2 5-bromopyridine-3-ol 
• 106-94-5 propyl bromide 

Downstream Products

• 934537-53-8 3-(5-propoxypyridin-3-yl)benzaldehyde 

Relevant articles and documents

ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE

The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3Kγ. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.

TETRAHYDROTHIAZOLOPYRIDINE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE

The present invention relates to compounds (I) useful as inhibitors of PBK, particularly of PI3K gamma. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders

TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS

The present invention relates to compounds useful as inhibitors of P13K, particularly of P13Kgamma. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of several diseases, such as cancer and autoimmune diseases.

Octahydropyrrolo[3,4-c]pyrrole: A diamine scaffold for construction of either α4β2 or α7-selective nicotinic acetylcholine receptor (nAChR) ligands. Substitutions that switch subtype selectivity

A series of 5-(pyridine-3-yl)octahydropyrrolo[3,4-c]pyrroles have been prepared that exhibit high affinity to α4β2 and/or α7 nicotinic acetylcholine receptors (nAChRs). Simple substitution patterns have been identified that allow construction of ligands that are highly selective for either nAChR subtype. The effects of substitution on subtype selectivity provide some insight into the differences in the ligand binding domains of the α4β2 and R7 receptors, especially in regions removed from the cation binding pocket.

Application of fragment screening by X-ray crystallography to the discovery of aminopyridines as inhibitors of β-secretase

Fragment-based lead discovery has been successfully applied to the aspartyl protease enzyme β-secretase (BACE-1). Fragment hits that contained an aminopyridine motif binding to the two catalytic aspartic acid residues in the active site of the enzyme were the chemical starting points. Structure-based design approaches have led to identification of low micromolar lead compounds that retain these interactions and additionally occupy adjacent hydrophobic pockets of the active site. These leads form two subseries, for which compounds 4 (IC50 = 25 μM) and 6c (IC50 = 24 μM) are representative. In the latter series, further optimization has led to 8a (IC50 = 690 nM).

Diazabicyclic central nervous system active agents

Compounds of formula I pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.